Developing the market for new allergy vaccines is proving difficult and has claimed another casualty, the US marketing partnership between Merck & Co. Inc. and Denmark’s ALK-Abello A/S, with the US Big Pharma returning all rights to ALK’s sublingual allergy immunotherapy tablets (SLIT) in North America.
The discontinuation followed a review of Merck’s strategic priorities and, after a six-month transition period, the rights to the SLIT...